SpotitEarly Enters U.S. Market with $20.3M for AI & Canine-Powered Cancer Test

What You Should Know:

–  SpotitEarly, a biotech company pioneering a non-invasive approach to early cancer detection, has officially launched its U.S. operations following a $20.3 million funding round.

–  The company aims to revolutionize cancer screening through its breath-based diagnostic platform, which integrates advanced AI with canine scent detection to identify cancer-associated volatile organic compounds (VOCs) with 94% accuracy, as demonstrated in a 1,400-participant trial published in Nature’s Scientific Reports. Commercial availability in the U.S. is expected in 2026.

SpotitEarly Launches in U.S. with $20M+ to Transform At-Home Cancer Detection

SpotitEarly’s at-home test targets four of the most common cancers—breast, colorectal, prostate, and lung—offering a cost-effective and accessible alternative to current invasive and often underutilized methods. The diagnostic process involves a face mask breath sample analyzed by trained canines, with data interpreted by SpotitEarly’s proprietary LUCID AI system, which tracks thousands of behavioral and physiological indicators in real time.

The company has secured backing from leading investors including:

Hanaco VCMenomedin VCJeff Swartz (former CEO of Timberland)Avishai Abrahami (CEO of Wix.com)

It has also received several competitive grants, notably from the BIRD Foundation, which supports U.S.–Israel joint research and development.

As the cost of cancer care in the U.S. is projected to exceed $245 billion by 2030, SpotitEarly’s bio-AI hybrid solution addresses urgent demands for earlier, more efficient screening. According to Alon Lifshitz, Founding Partner at Hanaco Ventures, “SpotitEarly is closing a critical gap in preventative care with a solution that is non-invasive, scalable, and poised to save lives by enabling early diagnosis.”

To support U.S. expansion, SpotitEarly has added key experts to its scientific leadership, including:

Dr. David Sidransky, molecular genetics pioneerJonathan Fleming, senior MIT lecturer and seasoned medtech investorDr. Len Lichtenfeld, former Deputy Chief Medical Officer at the American Cancer Society, who now serves as SpotitEarly’s Chief Medical Officer

The company is also establishing partnerships with major U.S. academic medical centers such as the University of Pennsylvania to expand research and validation efforts.

In parallel with the U.S. launch, SpotitEarly has opened a Regulation D Series A funding round for accredited investors.